1)Aghajanian GK, Marek GJ:Serotonin model of schizophrenia:emerging role of glutamate mechanisms. Brain Res Brain Res Rev 31:302-312, 2000
2)Andree TH, Mikuni M, Tong CY, et al:Differential effect of subchronic treatment with various neuroleptic agents on serotonin2 receptors in rat cerebral cortex. J Neurochem 46:191-197, 1986
3)Carlsson A, Hansson LO, Waters N, et al:Neurotransmitter aberrations in schizophrenia:new perspectives and therapeutic implications. Life Sci 61:75-94, 1997
4)Chouinard G, Jones BD, Annable L:Neuroleptic-induced supersensitivity psychosis. Am J Psychiatry 135:1409-1410, 1978
5)Demjaha A, Lappin JM, Stahl D, et al:Antipsychotic treatment resistance in first-episode psychosis:prevalence, subtypes and predictors. Psychol Med 47:1981-1989, 2017
6)Elsworth JD, Jentsch JD, Morrow BA, et al:Clozapine normalizes prefrontal cortex dopamine transmission in monkeys subchronically exposed to phencyclidine. Neuropsychopharmacology 33:491-496, 2008
7)Fujihara K, Miwa H, Kakizaki T, et al:Glutamate decarboxylase 67 deficiency in a subset of GABAergic neurons induces schizophrenia-related phenotypes. Neuropsychopharmacology 40:2475-2486, 2015
8)Howes OD, Kambeitz J, Kim E, et al:The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry 69:776-786, 2012
9)Ichikawa J, Meltzer HY:The effect of chronic clozapine and haloperidol on basal dopamine release and metabolism in rat striatum and nucleus accumbens studied by in vivo microdialysis. Eur J Pharmacol 176:371-374, 1990
10)Ichikawa J, Ishii H, Bonaccorso S, et al:5-HT(2A)and D(2)receptor blockade increases cortical DA release via 5-HT(1A)receptor activation:a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 76:1521-1531, 2001
11)飯塚幸彦,宮城島久海,笹島隆義:治療抵抗性統合失調症患者を対象としたclozapineの製造販売後調査結果(中間集計).臨床精神薬理 19:859-876, 2016
12)伊豫正臣:治療抵抗性統合失調症とドパミン過感受性精神病.精神医学 60:291-299, 2018
13)Kane J, Honigfeld G, Singer J, et al:Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796, 1988
14)Leysen JE, Niemegeers CJ, Tollenaere JP, et al:Serotonergic component of neuroleptic receptors. Nature 272:168-171, 1978
15)Lieberman J, Chakos M, Wu H, et al:Longitudinal study of brain morphology in first episode schizophrenia. Biol Psychiatry 49:487-499, 2001
16)Meltzer HY, Matsubara S, Lee JC:Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251:238-246, 1989
17)Meltzer HY, Massey BW:The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol 11:59-67, 2011
18)Mikuni M, Meltzer HY:Reduction of serotonin-2 receptors in rat cerebral cortex after subchronic administration of imipramine, chlorpromazine, and the combination thereof. Life Sci 34:87-92, 1984
19)三國雅彦:厚生労働省科学研究費補助金 障害者対策総合研究事業「治療抵抗性統合失調症に対する治療戦略のためのデータベース構築に関する研究.課題番号H22—精神—一般—010」平成22年度〜24年度総合研究報告書,平成25年3月
20)Muguruza C, Moreno JL, Umali A, et al:Dysregulated 5-HT(2A) receptor binding in postmortem frontal cortex of schizophrenic subjects. Eur Neuropsychopharmacol 23:852-864, 2013
21)Murray RM:Mistakes I have made in my research career. Schizophr Bull 43:253-256, 2017
22)Nakata Y, Kanahara N, Iyo M:Dopamine supersensitivity psychosis in schizophrenia:Concepts and implications in clinical practice. J Psychopharmacol 31:1511-1518, 2017
23)Ngan ET, Yatham LN, Ruth TJ, et al:Decreased serotonin 2A receptor densities in neuroleptic-naive patients with schizophrenia:A PET study using[(18)F]setoperone. Am J Psychiatry 157:1016-1018, 2000
receptors. J Neurosci 30:2211-2222, 2010
receptors. Eur J Pharmacol 89:325-326, 1983
26)Ronaldson KJ, Fitzgerald PB, Taylor AJ, et al:A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls. Aust N Z J Psychiatry 45:458-465, 2011
27)Sakai T, Oshima A, Nozaki Y, et al:Changes in density of calcium-binding-protein-immunoreactive GABAergic neurons in prefrontal cortex in schizophrenia and bipolar disorder. Neuropathology 28:143-150, 2008
28)Sumiyoshi T, Matsui M, Nohara S, et al:Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry 158:1722-1725, 2001
29)諏訪望:精神疾患の薬物療法—自律神経遮断剤を中心として.精神経誌 59:1173-1207, 1957
30)諏訪望:最終講義:精神医学における一つの考え方.諏訪 望教授退官記念北海道大学医学部精神医学教室研究診療業績録,1975
31)Tanii Y, Nishikawa T, Hashimoto A, et al:Stereoselective antagonism by enantiomers of alanine and serine of phencyclidine-induced hyperactivity, stereotypy and ataxia in the rat. J Pharmacol Exp Ther 269:1040-1048, 1994
32)Tiihonen J, Lönnqvist J, Wahlbeck K, et al:11-year follow-up of mortality in patients with schizophrenia:a population-based cohort study(FIN11 study).Lancet 374:620-627, 2009
33)Tiihonen J, Mittendorfer-Rutz E, Majak M, et al:Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatry 74:686-693, 2017
34)Volk DW, Austin MC, Pierri JN, et al:Decreased glutamic acid decarboxylase 67 neurons in subjects with schizophrenia. Arch Gen Psychiatry 57:237-245, 2000
35)Woo TU, Kim AM, Viscidi E:Disease-specific alterations in glutamatergic neurotransmission on inhibitory interneurons in the prefrontal cortex in schizophrenia. Brain Res 1218:267-277, 2008
36)Woo TU, Spencer K, McCarley RW:Gamma oscillation deficits and the onset and early progression of schizophrenia. Harv Rev Psychiatry 18:173-189, 2010